A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2010 Status changed from active, no longer recruiting to completed, according to Harbor BioSciences media release.
13 May 2010 Actual numebr of patients changed from 180 to 164, according to Harbor BioSciences media release.
12 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported in a Hollis-Eden Pharmaceuticals media release. Hollis-Eden Pharmaceuticals plan to complete this trial in Quarter 1 2010.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com